Skip to main content
. 2015 Apr 10;112(15):262–270. doi: 10.3238/arztebl.2015.0262

Figure.

Figure

Benefit–risk analysis to decide the indication for allogeneic SCT

The indication is determined on an individual basis for each patient and should be discussed with the patient and his/her family members. GvM, graft-versus-malignancy; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; SCT, stem cell transplantation